Výsledky vyhledávání - "Efthimios Kostouros"

Akademický článek

The Development of an Angiogenic Protein 'Signature' in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.

Autor: Sofia-Paraskevi Trachana, Eleftherios Pilalis, Nikos G Gavalas, Kimon Tzannis, Olga Papadodima, Michalis Liontos, Alexandros Rodolakis, Georgios Vlachos, Nikolaos Thomakos, Dimitrios Haidopoulos, Maria Lykka, Konstantinos Koutsoukos, Efthimios Kostouros, Evagelos Terpos, Aristotelis Chatziioannou, Meletios-Athanasios Dimopoulos, Aristotelis Bamias

Publikováno v: PLoS ONE, Vol 11, Iss 6, p e0156403 (2016)

Advanced ovarian cancer (AOC) is one of the leading lethal gynecological cancers in developed countries. Based on the important role of angiogenesis in ovarian cancer oncogenesis and expansion, we hypothesized that the development of an "angiogenic s

Externí odkaz: https://doaj.org/article/edeca7d62310417fb6160bc1ddabc3d6

Zobrazit plný text záznamu

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens

Autor: Evangelos Terpos, Efthimios Kostouros, Tina Bagratuni, Maria Gavriatopoulou, Maria Roussou, Efstathios Kastritis, Marianna Politou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanelias

Publikováno v: American Journal of Hematology. 88:765-770

Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE). In this study, we assessed clinical and genetic risk factors that may predispose for VTE in myeloma patients who were trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c326288b17e7281bb3b98235b9c4e25f
https://doi.org/10.1002/ajh.23504

Zobrazit plný text záznamu

The Development of an Angiogenic Protein 'Signature' in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling

Autor: Aristotelis Bamias, Nikos G. Gavalas, Alexandros Rodolakis, Michalis Liontos, Dimitrios Haidopoulos, Aristotelis Chatziioannou, E Terpos, Georgios D. Vlachos, Nikolaos Thomakos, Maria Lykka, Olga Papadodima, Konstantinos Koutsoukos, Meletios-Athanasios Dimopoulos, Sofia-Paraskevi Trachana, Eleftherios Pilalis, Efthimios Kostouros, Kimon Tzannis

Publikováno v: PLoS ONE
PLoS ONE, Vol 11, Iss 6, p e0156403 (2016)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78fe5ad52936791c5df97dca28abace9
http://europepmc.org/articles/PMC4892506

Zobrazit plný text záznamu

Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents

Autor: Konstantina Kakoyianni, Alexandros Rodolakis, George Vlahos, Efthimios Kostouros, Dimitrios Haidopoulos, Flora Zagouri, Aristotle Bamias, Meletios-Athanasios Dimopoulos, Christine Bamia, Nikolaos Thomakos, Aris Antsaklis

Publikováno v: Oncology. 84:158-165

Objective: The prognosis for patients with platinum-resistant advanced ovarian cancer remains poor. The impact of approved agents on survival has not been clarified during the last decade. We studied survival trends during the last 15 years in platin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05958c199417d4a673b36555f81365b3
https://doi.org/10.1159/000341366

Zobrazit plný text záznamu

Platinum-based therapy and oral cyclophosphamide as salvage therapy in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients with poor performance status and bulky/LN/visceral disease

Autor: Eftychia Kafantari, Evangelos Bournakis, Aristotelis Bamias, Eleni Efstathiou, Efthimios Kostouros, Meletios A. Dimopoulos, Revekka Gyftaki

Publikováno v: Journal of Clinical Oncology. 32:e16096-e16096

e16096 Background: platinum based therapy is a potentially valid choice for heavily pretreated mCRPC patients (pts) whose disease progresses with anaplastic features. Methods: This is a retrospecti...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6169e775226d31fc0ad8dee296282fc9
https://doi.org/10.1200/jco.2014.32.15_suppl.e16096

Zobrazit plný text záznamu

Development and validation of prognostic models in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib: A Greek-French collaboration

Autor: Antonios Visvikis, Reza-Thierry Elaidi, Eleni Timotheadou, George Fountzilas, Constantinos Hatzimouratidis, George Lazaridis, Meletios A. Dimopoulos, Efthimios Kostouros, K. Stravodimos, Evangelia Razis, D.V. Skarlos, Aristotelis Bamias, Stéphane Oudard, Vasilios Karavasilis, Helena Linardou, Kimon Tzanis, Christina Bamia, Michael Chrisofos

Publikováno v: Journal of Clinical Oncology. 30:e15040-e15040

e15040 Background: The use of tyrosine kinase inhibitors (TKIs) in mRCC has improved prognosis but the individual outcome remains largely unpredictable. The MSKCC model, used to identify risk groups, was developed in cytokine-treated patients and has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::23cd4b88d528b8f317e9b81a12c29eaf
https://doi.org/10.1200/jco.2012.30.15_suppl.e15040

Zobrazit plný text záznamu

Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations

Autor: Marianna Politou, Maria Roussou, Efthimios Kostouros, Evangelos Terpos, Meletios A. Dimopoulos, Tina Bagratuni, Efstathios Kastritis, Dimitrios Christoulas

Publikováno v: Blood. 118:2872-2872

Abstract 2872 The introduction of IMiDs (thalidomide, lenalidomide and recently pomalidomide) has been a major advance in the treatment of multiple myeloma. These agents have shown significant efficacy both in the relapsed/refractory setting and at t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e6bbde05769e7118a26523479b86ff
https://doi.org/10.1182/blood.v118.21.2872.2872

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání